Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 0.60 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 14/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22653545 | 1.00 | BCL2L1 (0.60) | BCL2L1SFRP1BCL2MCL1BCL2L2 | |
| SCHEMBL22581289 | 0.90 | BCL2L1 (0.66) | BCL2L1BCL2 | |
| SCHEMBL28716010 | 0.90 | BCL2L1 (0.66) | BCL2L1BCL2 | |
| SCHEMBL22581205 | 0.90 | BCL2L1 (0.74) | BCL2L1BCL2 | |
| SCHEMBL22581203 | 0.90 | BCL2L1 (0.74) | BCL2L1BCL2 | |
| SCHEMBL554919 | 0.88 | BCL2L1 (0.75) | BCL2L1BCL2 | |
| SCHEMBL554918 | 0.88 | BCL2L1 (0.75) | BCL2L1BCL2 | |
| SCHEMBL15514753 | 0.86 | BCL2L1 (0.61) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL15514754 | 0.86 | BCL2L1 (0.61) | BCL2L1BCL2MCL1BCL2L2 | |
| SCHEMBL26648676 | 0.85 | BCL2L1 (0.67) | BCL2L1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50643-E1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4556469-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-3740487-B1 | BENZAMIDE COMPOUNDS AS BCI INHIBITORS FOR THE TREATMENT OF HIV | RECURIUM IP HOLDINGS LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2024-06-06 | — | — | US | disclosed |
| CN-118084904-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084905-A | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-111801327-B | Benzamide compounds | 里科瑞尔姆IP控股有限责任公司 | 2024-02-09 | — | — | CN | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-11590126-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | RECURIUM IP HOLDINGS, LLC | 2022-09-01 | — | — | US | disclosed |
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2022-08-25 | — | — | US | disclosed |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | RECURIUM IP HOLDINGS, LLC | 2022-07-21 | — | — | US | disclosed |
| US-11344546-B2 | Benzamide compounds | Recurium IP Holding, LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-11318134-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2022-05-03 | — | — | US | disclosed |
| EP-3740487-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3737672-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3737681-A1 | BENZAMIDE COMPOUNDS | Recurium IP Holdings, LLC (US) | 2020-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885SFRP1 4654/4885BCL2 69/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885SFRP1 4654/4885BCL2 69/4885 |
| US-20220265834-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885SFRP1 3516/4885BCL2 1/4885 |
| US-11590126-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885SFRP1 4654/4885BCL2 69/4885 |
| US-11318134-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885SFRP1 4654/4885BCL2 69/4885 |
| US-20220273666-A1 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR | BCL2, BCL2L2, BCL2L1 | BCL2L1 3/4885SFRP1 1699/4885BCL2 1/4885 |
| US-20220226314-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885SFRP1 4654/4885BCL2 69/4885 |
| US-20240180899-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885SFRP1 4654/4885BCL2 69/4885 |
| US-11344546-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BCL2L1 86/4885SFRP1 4654/4885BCL2 69/4885 |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | BCL2L1 2/4885SFRP1 3578/4885BCL2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.